Pharma Industry News

Biotechnology: The trials of Juno

Written by David Miller

Print section
Print Rubric: 

A young biotech firm focused on cancer promises both risk and reward

Print Headline: 

The trials of Juno

Print Fly Title: 

Biotechnology

UK Only Article: 
standard article

Issue: 

The threat from Russia

Fly Title: 

Biotechnology

Main image: 

20161022_wbp501_hr.jpg

IN THE pharma business, Juno Therapeutics, a small firm based in Seattle, is just a stripling. It is three years old, has not a single drug approval to its name but is nonetheless valued at $2.8 billion. That value is derived from the fact that it is on the forefront of the most promising area of cancer treatments in decades: immuno-oncology.
Juno’s edge comes from its attempts to master one of the most important parts of the immune system: the T-cell. It is developing a so-called CAR-T therapy, in which its scientists extract T-cells from a cancer patient, modify them with …Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]